Title | STAT3 signaling in polycystic kidney disease |
Publication Type | Journal Article |
Year of Publication | 2013 |
Authors | Weimbs, T, Talbot, JJ |
Journal | Drug Discovery Today: Disease Mechanisms |
Volume | 10 |
Start Page | e113 |
Issue | 3-4 |
Pagination | e113-e118 |
Abstract | Mutations in the gene coding for the integral membrane protein polycystin-1 (PC1) are the cause of most cases of autosomal-dominant polycystic kidney disease (ADPKD), a very common disease that leads to kidney failure and currently lacks approved treatment. Recent work has revealed that PC1 can regulate the transcription factor STAT3, and that STAT3 is aberrantly activated in the kidneys of ADPKD patients and PKD mouse models. Recent approaches to directly inhibit STAT3 in PKD mouse models have been promising. Numerous signaling pathways are known to activate STAT3 and many have long been implicated in the pathogenesis of PKD – such as EGF/EGFR, HGF/c-Met, Src. However, a role of STAT3 in the pathogenesis of PKD had never been considered until now. Here, we review the current findings that suggest that STAT3 is a promising target for the treatment of PKD. |